 |
      |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Your eyes naturally contain fluid called aqueous humor, which keeps them nourished and healthy. Normally, this fluid flows and drains freely. In patients with glaucoma, the fluid does not drain properly. This buildup of fluid causes increased pressure inside the eye and is referred to as elevated intraocular pressure, or IOP. If IOP remains elevated, it can permanently damage the optic nerve and impair your vision. While there is no cure for glaucoma, studies show that IOP-lowering medications can help to delay or prevent the development of glaucoma and its associated vision loss.1-3 |
 |
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Please click here for full product information. 1. The AGIS Investigators. The Advanced Glaucoma Invervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. 2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; for Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. 3. Kass MA, Heuer DK, Higginbotham EJ, et al; for Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713. |
|
©2009 Allergan, Inc., Irvine, CA 92612 | ® marks owned by Allergan, Inc. |